Top Markets
#1 Purr Purr +62.18%
#2 Smilek to the Bank Smilek to the Bank +50.56%
#3 Pons Pons +27.54%
#4 Kinetiq Kinetiq +24.51%
#5 ApeX ApeX +23.35%
#6 Fake World Assets Fake World Assets +19.18%
#7 Zora Zora +18.85%
#8 Non-Playable Coin Non-Playable Coin +18.72%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +18.50%
#10 OriginTrail OriginTrail +18.33%
Coin of the day
Purr Purr
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Talaris Therapeutics, Inc. Talaris Therapeutics, Inc.

Talaris Therapeutics, Inc.

TALS
Pozycja w akcjach #21258
Talaris Therapeutics, Inc. is a cell therapy company operating in the United... Talaris Therapeutics, Inc. is a cell therapy company operating in the United States, currently in its late clinical development stages. Its mission involves pioneering an allogeneic hematopoietic stem cell transplantation strategy designed to revolutionize treatment paradigms for solid organ transplantation, severe autoimmune conditions, and significant non-malignant blood, immune, and metabolic disorders. The company's flagship product, FCR001, is an innovative allogeneic cell therapy presently in Phase II clinical trials for patients undergoing living donor kidney transplantation. Beyond this, Talaris Therapeutics is actively advancing FCR002 for use in deceased donor kidney transplants, investigating FCR001 for individuals with a severe form of scleroderma, and exploring its applicability for a range of other serious non-malignant blood, immune, or metabolic conditions. Founded in 1988, the company maintains its headquarters in Louisville, Kentucky.
Cena akcji
$2.72
Ostatnia synchronizacja: 2023-10-19
Kapitalizacja rynkowa
$111.47M
Zmiana (1 dzień)
-0.73%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Talaris Therapeutics, Inc. (TALS)

Kategoria

Healthcare
Zyski dla Talaris Therapeutics, Inc. (TALS)
Zyski w 2026 TTM: 0
Według najnowszych raportów finansowych Talaris Therapeutics, Inc., obecny zysk firmy wynosi 0. W roku 2026 firma osiągnęła zysk w wysokości 0, równa się zysku z roku 2026, który wynosił 0. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Talaris Therapeutics, Inc. od 2026 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
Za mało danych dla podanych dat.
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH